RC
REGN icon

Rexford Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Rexford Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$183K Hold
294
– – 0.11% 182
2026
Q1 		$227K Buy
294
+6
+2% +$4.59K 0.16% 157
2025
Q4 		$222K Buy
288
+15
+5% +$10.2K 0.17% 155
2025
Q3 		$154K Hold
273
– – 0.12% 193
2025
Q2 		$143K Buy
+273
New +$152K 0.12% 191

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rexford Capital's REGN Position: Q2 2026 in Review

Rexford Capital held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 294 shares worth $183K. The position accounts for 0.11% of the portfolio, ranked #182.

Rexford Capital first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $227K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Rexford Capital held 294 shares of Regeneron Pharmaceuticals worth $183K as of Q2 2026.
  • Rexford Capital left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.11% of Rexford Capital's portfolio in Q2 2026, its #182 holding.
  • Rexford Capital first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Rexford Capital's Regeneron Pharmaceuticals position peaked at $227K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Rexford Capital's 13F filing for Q2 2026, filed 29 Jul 2026.